Over the last two decades, cardiology practice has become increasingly biomarker-driven, particularly in suspected acute coronary syndrome (ACS), high-sensitivity cardiac troponin (hs-cTn) assays, and in heart failure evaluation, natriuretic peptides have become central components of diagnostic algorithms. This transformation has also brought an evolution from classical enzyme biomarkers to the current generation of hs-cTn assays, enabling earlier diagnosis, improved risk stratification, and faster therapeutic decision-making [1]. However, as sensitivity increases, interpretation of low-level biomarker changes has become more critical, and the impact of erroneous results on patient management has grown [2].

As immunoassay-based measurements gain importance in clinical decision-making, analytical accuracy and management of interference-related errors have become an essential part of patient safety in cardiology. Immunoassay interference may lead to serious consequences such as unnecessary invasive procedures, incorrect labeling of myocardial injury, inappropriate antithrombotic or anti-ischemic treatments, and avoidable hospitalizations [3]. Therefore, when laboratory results are inconsistent with the clinical presentation, the possibility of analytical interference should always be considered [3].

Among immunoassay interferences, heterophile antibodies remain a recognized but often underappreciated source of analytical interference, even in modern assays that are considered highly specific. Heterophile antibodies can interact with animal-derived antibodies used in assays with weak or multispecific binding and, particularly in sandwich immunometric assay designs, can generate false analytical signals, resulting in either false-positive or false-negative results [4]. In cardiac troponin measurements, clinically implausible and persistent elevations related to heterophile antibody interference have been reported, clearly demonstrating the risk of inappropriate ACS management [5, 6]. A recent case showing a 4-year-long elevation of hs-troponin due to heterophile antibodies further highlights the ongoing clinical relevance of this issue [7].

Although heterophile antibody interference is generally considered uncommon, its reported frequency varies across studies depending on assay architecture, detection strategies, and patient populations. Estimates from laboratory-based investigations suggest interference rates ranging from approximately 0.05% to 3% in immunoassay measurements, although the true prevalence is likely underestimated because many cases remain clinically unrecognized [8–13]. Importantly, even low-frequency interference may have disproportionate clinical consequences when high-stakes biomarkers such as cardiac troponins or natriuretic peptides are involved. A summary of representative frequency estimates reported in the literature is presented in Table 1.

This narrative review was conducted through a comprehensive search of PubMed, Scopus, and Web of Science databases using combinations of keywords including heterophile antibodies, immunoassay interference, cardiac troponin, natriuretic peptides, and analytical error. Original research articles, case reports, systematic reviews, and relevant laboratory medicine guidelines published in English were screened for clinical relevance. References of selected papers were additionally hand-searched to identify further pertinent studies. Emphasis was placed on reports demonstrating clinical consequences, diagnostic challenges, and practical confirmation strategies related to heterophile antibody interference in cardiac biomarker testing. The literature search covered studies published up to January 2026. Priority was given to clinically relevant original studies, case series, systematic reviews, and guideline-based laboratory medicine recommendations focusing on cardiac biomarker testing and immunoassay interference. Publications were selected based on their relevance to mechanisms of interference, diagnostic implications, and practical confirmation strategies in cardiovascular clinical settings.

The aim of this review is to systematically summarize the mechanisms by which heterophile antibodies cause interference in immunoassays, the diagnostic pitfalls they create in cardiac biomarkers (particularly troponin and natriuretic peptides), and their impact on clinical decision-making. Additionally, practical suspicion and verification strategies that strengthen clinician-laboratory collaboration will be discussed.

Heterophile antibodies are endogenous immunoglobulins capable of binding to animal-derived antibodies used in immunoassays, leading to potential assay interference. These antibodies may occur naturally or may develop following exposure to animal antigens through environmental contact, therapeutic monoclonal antibody treatments, or diagnostic procedures. In addition, the likelihood of antibody-mediated interference may be increased in patients with autoimmune diseases, recent or recurrent viral infections, or immune responses related to certain medications, including over-the-counter preparations [9, 10, 14]. Their presence can cause non-specific binding within immunoassays and may result in either falsely elevated or falsely decreased analyte measurements [14].

The main mechanism of heterophile antibody interference involves their ability to cross-link capture and detection antibodies in sandwich immunoassay formats. In this situation, heterophile antibodies create an artificial bridge between assay antibodies even when the target analyte is absent, leading to false signal generation and falsely elevated results [9]. Conversely, in some cases, heterophile antibodies may block the interaction between the analyte and assay antibodies, producing falsely low measurements. The magnitude of interference depends on antibody affinity, concentration, and assay design characteristics [14, 15].

Human anti-animal antibodies (HAAAs), including human anti-mouse antibodies (HAMAs), represent a clinically important subgroup of heterophile antibodies. HAMA-related interference is particularly relevant because many monoclonal antibodies used in immunoassays are derived from murine hybridoma technology, which increases the likelihood of interaction with circulating anti-mouse antibodies [16]. When assay antibodies originate from other species, the probability and pattern of interference may differ depending on the antibody source and assay design characteristics [9]. These antibodies usually develop after therapeutic or diagnostic exposure to animal-derived immunoglobulins and are well known to cause clinically significant immunoassay interference [17]. This is particularly relevant in cardiac biomarker assays such as troponin measurements, where analytical accuracy is critical for diagnosis and treatment decisions [18].

Although heterophile antibodies and HAAAs are closely related, they are not identical entities. Heterophile antibodies are typically naturally occurring, low-affinity, multispecific antibodies that can bind assay antibodies from different animal species, whereas HAAAs usually develop after exposure to therapeutic or diagnostic animal-derived immunoglobulins and tend to show greater specificity [4]. In addition, other causes of analytical interference, such as macrotroponin formation, represent a different mechanism involving circulating macromolecular complexes rather than antibody-mediated assay bridging [9, 17]. Distinguishing between these mechanisms is important because their diagnostic confirmation strategies and clinical implications may differ.

Several strategies have been developed to reduce heterophile antibody interference. These include the use of heterophile blocking reagents, assay redesign using antibody fragments or modified antibody structures, and confirmation of suspicious results using alternative assay platforms or methodologies [18]. Despite these preventive measures, heterophile antibody interference continues to represent an important analytical challenge in clinical immunoassay testing, requiring close collaboration between clinicians and laboratory specialists [8, 9, 14–18].

Heterophile antibodies interfere with immunoassays through several biochemical and structural mechanisms, most prominently by disrupting antigen-antibody binding dynamics in sandwich assay configurations. The most widely recognized mechanism is the bridging of capture and detection antibodies, where heterophile antibodies bind simultaneously to both assay antibodies, generating a signal in the absence of the target analyte. This leads to falsely elevated biomarker concentrations and may mimic clinically significant disease states [8, 17]. The major biochemical and structural pathways through which heterophile antibodies disrupt immunoassay performance are summarized in Table 2.

In contrast, heterophile antibodies may also cause false-negative results. This occurs when these antibodies block antigen-binding sites or sterically hinder analyte interaction with assay antibodies, preventing proper immune complex formation. The direction and magnitude of interference depend on multiple factors, including antibody specificity, epitope accessibility, and assay reagent composition [8, 18].

Assay design plays a critical role in susceptibility to heterophile antibody interference. Sandwich immunoassays are generally more vulnerable compared with competitive immunoassays because they rely on simultaneous binding of two antibodies to generate measurable signals. High-sensitivity assays, which use lower detection thresholds and signal amplification strategies, may be particularly prone to detecting low-level nonspecific interactions caused by heterophile antibodies [10, 17].

Another key determinant is antibody affinity and concentration. High-affinity heterophile antibodies can create stable non-specific immune complexes, increasing the likelihood of persistent assay interference. Similarly, higher circulating concentrations of heterophile antibodies increase the probability of cross-reactivity with assay reagents. Patient-specific immunological variability, therefore, plays an important role in determining interference patterns and reproducibility [8, 12].

Platform-dependent effects are also clinically relevant. Different manufacturers use varying antibody sources, blocking reagents, and assay architectures, which may result in discordant results across platforms. When heterophile antibody interference is suspected, initial confirmatory approaches typically include polyethylene glycol (PEG) precipitation and the use of heterophile blocking reagents to remove or neutralize interfering antibodies before repeat measurement. Alternative assay platform testing may provide additional supportive information; however, inter-platform differences should be interpreted cautiously because assay-specific characteristics and reference intervals may vary. Lack of concordance between platforms can represent a useful supportive clue for analytical interference rather than true biomarker elevation when interpreted together with targeted laboratory confirmation strategies [10, 15, 17, 18].

Overall, heterophile antibody-mediated assay interference represents a complex interaction between patient immunology and assay engineering. Understanding these mechanisms is essential for recognizing unexpected laboratory results and preventing diagnostic errors, particularly in high-stakes clinical settings such as emergency cardiology and ACS evaluation [8, 10].

Heterophile antibody interference has been described across a range of cardiac and cardiovascular-relevant immunoassays, but the clinical impact is greatest when biomarkers directly trigger high-stakes decisions in emergency cardiology or long-term disease management. Among these, cardiac troponins and natriuretic peptides are particularly vulnerable because they are often interpreted as objective evidence of myocardial injury or hemodynamic stress, respectively, and are frequently acted upon without delay [19–21].

Recognizing heterophile antibody interference requires a high index of suspicion, especially when biomarker results are discordant with the overall clinical assessment. A major red flag is an apparently abnormal cardiac biomarker in a patient whose symptoms, electrocardiogram, imaging, and overall clinical trajectory do not support the laboratory finding. In the era of high-sensitivity troponin assays, small numerical elevations can occur for many reasons, but a result that is persistently “abnormal” without a coherent clinical explanation should prompt consideration of analytical interference [34, 35].

Another important warning sign is the absence of expected biomarker kinetics. In true acute myocardial infarction, troponin typically demonstrates a rise and/or fall pattern over serial sampling, and clinical decision pathways rely heavily on these temporal changes. When serial measurements remain stable at an unusual “plateau” level, particularly if the timing of symptoms does not match the biomarker pattern, interference should be considered alongside alternative biological explanations [34, 36].

Certain patient-related factors may increase the likelihood of heterophile antibody interference. These include exposure to therapeutic monoclonal antibodies, autoimmune diseases, recent or chronic viral infections, repeated diagnostic procedures involving animal-derived antibodies, and occupational or environmental animal antigen exposure [4, 17]. In addition, assay-related characteristics such as sandwich immunoassay architecture, antibody source variability, and platform-specific blocking strategies may influence susceptibility to interference [10, 32]. Awareness of these clinical and analytical risk factors may facilitate earlier recognition of unexpected laboratory results.

Inter-assay or inter-platform discordance is a particularly valuable clue. If repeated testing using a different manufacturer’s platform yields markedly different values, this strongly supports an analytical artifact rather than true myocardial injury. A recent PubMed-indexed case report highlighted that discrepant troponin results across assays were the key trigger for investigating heterophile antibody interference and avoiding misdiagnosis [37].

Additional red flags include persistently abnormal results despite resolution of symptoms or normalization of other clinical parameters, particularly when repeated investigations remain inconclusive. Such scenarios increase the risk of unnecessary invasive testing, inappropriate antithrombotic therapy, and avoidable hospitalizations, underscoring the need to integrate clinical judgment with laboratory interpretation [34, 37].

Although heterophile antibody interference is generally considered uncommon, reported prevalence varies substantially across assay platforms, analytical designs, and study populations. Available laboratory-based estimates suggest frequencies ranging from approximately 0.05% to 3%, but the true prevalence is likely underestimated because many cases remain clinically unrecognized or are not systematically investigated [8]. Importantly, even low-frequency interference may have disproportionate clinical consequences when high-stakes biomarkers such as cardiac troponins or natriuretic peptides are involved. Therefore, clinicians should interpret unexpected or discordant biomarker results cautiously and consider analytical interference even when the estimated probability appears low.

Finally, clinicians should remember that heterophile antibodies can affect other cardiovascular-relevant immunoassays as well; therefore, a broader “interference mindset” is warranted when laboratory findings repeatedly conflict with the clinical picture [38]. An integrated overview of suspected interference patterns and confirmation strategies is presented in Figure 1.

When heterophile antibody interference is suspected, confirmation requires a structured laboratory approach combined with close communication between clinicians and laboratory professionals. Because no single test definitively proves interference, a stepwise diagnostic strategy is recommended, integrating clinical suspicion with targeted analytical verification methods [39, 40].

PEG precipitation represents one of the practical early confirmatory techniques, particularly when macromolecular complexes are suspected. PEG precipitation has also been incorporated into interference investigations involving high-sensitivity troponin assays. In a PubMed-indexed report describing heterophile antibody interference affecting hs-cTnT measurements, pretreatment strategies led to a marked reduction in the apparent troponin concentration, supporting analytical rather than biological elevation [41]. A decrease in measured biomarker concentration exceeding approximately 20% after PEG precipitation supports the presence of antibody-mediated interference and suggests that the original result may be analytically unreliable [15, 17].

Another important strategy involves the use of heterophile antibody blocking reagents (e.g., heterophile blocking reagent/tubes). These reagents are designed to neutralize heterophile antibody activity and thereby reduce non-specific antibody binding within immunoassays. A substantial reduction in the reported analyte concentration after pretreatment supports the presence of heterophile-mediated interference and may be decisive when laboratory findings are inconsistent with the clinical presentation [40, 41].

Serial dilution testing is also widely used in interference investigations. In true analyte measurement, serial dilution typically produces approximately linear results after adjustment for the dilution factor. In contrast, nonlinearity following dilution suggests the presence of heterophile antibodies or related endogenous interfering factors. Dilution studies are particularly useful when blocking reagents are unavailable or when additional analytical confirmation is required to support suspected interference [40].

Repeating the measurement using an alternative assay platform represents another practical component of the verification strategy. Different manufacturers employ distinct antibody sources, assay architectures, and blocking approaches. Therefore, clinically relevant discrepancies between platforms strongly suggest analytical interference rather than true biomarker elevation. Cross-platform comparison is especially valuable in suspected cases of troponin interference, where rapid clarification may help prevent unnecessary invasive investigations [39, 40].

In practical clinical settings, a stepwise workflow may improve recognition and confirmation of suspected interference. First, clinicians should reassess clinical-biochemical concordance and evaluate whether observed biomarker kinetics are physiologically plausible. Second, laboratory-based confirmation may begin with PEG precipitation when antibody-mediated interference is suspected. Third, heterophile antibody blocking reagent treatment can help demonstrate signal suppression attributable to interfering antibodies. Fourth, serial dilution testing may be performed to assess analytical linearity. Finally, repeat measurement using an alternative assay platform or consultation with laboratory specialists may be required in unresolved cases [15, 17, 39–41]. A structured workflow integrating these steps may help avoid unnecessary invasive procedures and reduce diagnostic uncertainty.

Overall, confirming heterophile antibody interference requires integration of clinical reasoning with method-specific analytical verification tools. Early recognition and appropriate laboratory confirmation can prevent repeated emergency presentations, unnecessary invasive procedures, inappropriate pharmacologic therapy, and long-term diagnostic labeling driven by spurious biomarker results [39, 42]. A structured approach to suspicion and laboratory confirmation of heterophile antibody interference, including PEG precipitation, blocking reagents, dilution-based techniques, and platform comparison, is outlined in Table 4.

Heterophile antibody-mediated assay interference can directly compromise patient safety because cardiac biomarkers frequently trigger time-sensitive, high-stakes decisions. When falsely elevated results are interpreted as true myocardial injury or decompensated cardiovascular disease, patients may be exposed to unnecessary diagnostic procedures, inappropriate treatments, and avoidable hospitalization [43–45].

Unnecessary invasive investigations represent one of the most serious consequences. A case report described a patient who underwent coronary angiography solely due to false-positive troponin I results, illustrating how analytical artifacts can precipitate invasive testing with associated procedural risks and costs [43]. Similarly, a published case report described repeated clinical concern and diagnostic investigations driven by heterophile antibody-related false-positive troponin elevation, highlighting that unrecognized assay interference can result in recurrent presentations and repeated escalation of care [44].

Overtreatment is another major patient-safety issue. False-positive troponin values may trigger ACS pathways, including antiplatelet and anticoagulant therapy, which carry bleeding risks and may complicate future procedures. Even when clinicians ultimately determine that angiography is normal, the initial laboratory signal can still drive prolonged observation, serial testing, and exposure to medications that confer harm without benefit [44, 45].

Beyond immediate clinical harm, heterophile interference creates a psychological and economic burden. Patients may experience significant anxiety from being labeled with “myocardial infarction” or “chronic myocardial injury,” and may undergo repeated follow-up visits and testing. Health systems may incur avoidable expenditures related to admissions, imaging, and invasive procedures performed in response to spurious laboratory signals [45].

At the healthcare-system level, heterophile antibody interference may also increase diagnostic workload, prolong emergency department observation times, trigger avoidable imaging procedures, and generate unnecessary invasive testing such as coronary angiography. These effects contribute to increased healthcare costs and inefficient resource utilization, particularly in high-volume emergency cardiology settings where biomarker-driven decision pathways are routinely applied [43–45].

Finally, persistent assay interference can create long-term diagnostic confusion. Reports involving interference-related discrepancies (including macrocomplex-related troponin artifacts) show that patients may undergo prolonged or repeated investigations unless interference is systematically considered and resolved through clinician-laboratory collaboration [41]. Collectively, these impacts highlight why analytical interference should be treated as a patient-safety issue rather than a purely laboratory concern [43–46].

Current cardiology and laboratory medicine guidance increasingly acknowledges the importance of analytical quality in cardiac biomarker interpretation, yet heterophile antibody interference is still not systematically embedded in most routine clinical pathways. Consensus documents emphasize that biomarkers, particularly cardiac troponins, must be interpreted in a clinical context, and that analytical causes of unexpected results should be considered when laboratory data are inconsistent with the patient’s presentation [47].

The Fourth Universal Definition of Myocardial Infarction underscores that a diagnosis of myocardial infarction requires evidence of myocardial injury in a compatible clinical setting and highlights the need to exclude alternative explanations when biomarker findings are incongruent. While heterophile antibodies are not a core focus of the document, it supports the broader principle that analytical false-positives must be considered before confirming myocardial injury in low-probability scenarios [47].

From the laboratory medicine perspective, guidance on immunoassays stresses that analytical errors and endogenous interferences can have clinically significant downstream consequences and therefore require proactive risk mitigation. Practical reviews outline how immunoassays remain vulnerable to occasional analytical errors and propose structured thinking to minimize risk, particularly when results are clinically implausible [48]. Additional perspective articles emphasize that interferences may represent rare but high-impact “black swan” events that can cause misdiagnosis or inappropriate treatment unless laboratories and clinicians actively consider and investigate them [49].

Despite this awareness, major gaps remain: There is no universally adopted, cardiology-specific algorithm for systematic detection and management of heterophile antibody interference in troponin or natriuretic peptide testing. As a result, recognition often depends on individual clinician suspicion and local laboratory expertise, which can delay resolution in acute care settings [48, 49].

Future progress in preventing heterophile antibody interference will likely require parallel advances in assay engineering, laboratory workflows, and data-driven surveillance. From an assay-design perspective, manufacturers are increasingly focused on reducing susceptibility through improved antibody selection, optimized blocking formulations, and refined architectures that minimize non-specific bridging. Because interference remains platform-dependent, broader transparency around assay antibody composition and blocking strategies could facilitate more predictable troubleshooting and cross-platform verification in suspected cases [50].

Laboratory practice is also evolving toward more standardized reflex pathways. When biomarker results are clinically discordant, structured workups, such as immediate retesting on an alternative platform, targeted pretreatment with blocking reagents, and dilution-based linearity checks, should become more consistently embedded into local protocols. Wider availability of validated interference investigation kits and clearer manufacturer guidance on their limitations could shorten time-to-resolution and reduce unnecessary downstream testing [50].

A major emerging direction is the integration of artificial intelligence (AI) into clinical laboratory medicine. AI-assisted systems may support anomaly detection by identifying result patterns that deviate from expected biological behavior and flagging outliers that could warrant interference workup, particularly in high-volume settings where rare events are easily missed [51]. In addition, machine learning approaches are currently being explored as potential tools to detect laboratory errors across the testing process, which may help distinguish physiological variation from analytical artifacts and prioritize cases for expert review [52].

Future research should also focus on establishing standardized diagnostic algorithms for suspected immunoassay interference in cardiac biomarker testing and improving collaboration between cardiology services and clinical laboratories. Prospective studies evaluating the real-world frequency and clinical consequences of heterophile antibody interference across different assay platforms would further help define its true impact and guide the development of practical clinical pathways [15, 17, 48, 49].

More broadly, recent advances in AI-supported cardiovascular prognostic modeling, personalized metabolic risk stratification, and circadian rhythm-informed prevention strategies illustrate how data-driven approaches are increasingly shaping precision cardiovascular medicine. Although these developments are not specific to immunoassay interference, they highlight the growing potential of integrative analytical frameworks to improve the interpretation of complex biomarker signals and reduce diagnostic uncertainty in future cardiology practice [53–55].

Overall, combining improved assay robustness with standardized investigative pathways and AI-enabled surveillance offers a realistic roadmap to reduce heterophile antibody-related diagnostic error in cardiology [50–52].

Heterophile antibody interference remains an important yet frequently underrecognized source of analytical error in cardiac biomarker testing. As cardiology becomes increasingly biomarker-driven, the clinical consequences of false-positive or false-negative laboratory results become more significant. hs-cTn assays and natriuretic peptide measurements, which play central roles in acute and chronic cardiovascular disease management, are particularly vulnerable to immunoassay interference.

Recognition of heterophile antibody interference requires integration of laboratory data with clinical context. Discordance between biomarker results and the patient’s symptoms, imaging findings, or expected biomarker kinetics should prompt consideration of analytical interference. Early suspicion and timely collaboration between clinicians and laboratory specialists are essential to avoid unnecessary invasive procedures, inappropriate pharmacologic therapy, and prolonged diagnostic uncertainty.

Future improvements in assay design, laboratory diagnostic pathways, and advanced data analytics may help reduce the impact of immunoassay interference. However, clinician awareness will remain a cornerstone of safe biomarker interpretation. Ultimately, strengthening clinic-laboratory communication and maintaining a structured approach to unexpected laboratory results will be critical to improving patient safety and diagnostic accuracy in modern cardiology practice.